Skip to main content
. 2019 Jul 1;9:9482. doi: 10.1038/s41598-019-45890-w

Figure 1.

Figure 1

Pharmacodynamics and pharmacokinetics of PC945 in an in vitro model of the human alveolus. (A) Time-dependent change of GM in lower chamber after azole-susceptible A. fumigatus infection to the upper chamber, n = 3, ***p < 0.001 vs. control (B) Concentration-dependent change of GM in lower chamber 24 h after azole-sensitive A. fumigatus (NCPF2010; ■) or azole-resistant A. fumigatus (TR34/L98H; □) inoculation to the upper chamber, n = 3, **p < 0.01 vs NCPF2010 control, ##p < 0.01 vs. L98H control (C) PC945 in cell membrane recovered 24 h after treatment to the upper chamber. (D) Correlation of PC945 cellular content with inhibition of A. fumigatus penetration to the lower chamber, (E) Retention of PC945 in the bilayer when treated for 2 h (▲) or 2 h plus 24 h washout (●), (F) PC945 in media of upper (■) and lower (▲) chamber recovered 24 h after treatment to the upper chamber.